We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 1.30% | 30.48 | 30.40 | 30.50 | 30.52 | 30.31 | 30.32 | 1,121,708 | 21:15:26 |
From May 2021 to May 2024
By Chris Wack
Atea Pharmaceuticals Inc. shares fell 16% to $9.53 after the company said its strategic collaboration with Roche to develop AT-527 to treat Covid-19 is ending in February.
The biopharmaceutical company said the rights and licenses granted to Roche will be returned to Atea, which will have full rights to continue the clinical development and future commercialization of AT-527 worldwide.
Atea said that as of Sept. 30 it had cash and cash equivalents of $839.7 million, with a cash runway through 2023.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 17, 2021 10:11 ET (15:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
